Activity – Page 9

LEO Pharma’s Acquisition of Timber Pharmaceuticals’ Assets Faces Setback Due to Late-Stage Study Failure

10 months ago talkbio0Tagged Acquisition (action), asset, Congenital ichthyosis, Failure (biologic function), late-stage study, Panthera leo, Pharma, Timber, TMB-001

LEO Pharma, Timber Pharmaceuticals, TMB-001, congenital ichthyosis, late-stage study failure, asset acquisition

Liquidia’s Yutrepia Receives Tentative FDA Approval Due to Tyvaso Exclusivity

10 months ago talkbio0Tagged 4-aminohippuric acid, exclusivity, Liquidia, PH-ILD, Pulmonary arterial hypertension, Tentative Approval, Tyvaso, United States Food and Drug Administration, YUTREPIA

Liquidia, Yutrepia, FDA, tentative approval, Tyvaso, exclusivity, pulmonary arterial hypertension, PAH, PH-ILD

FDA Grants Tentative Approval for YUTREPIA, a New Treatment for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease

10 months ago talkbio0Tagged Associated with, Lung Diseases, Interstitial, PH-ILD, Pulmonary arterial hypertension, Pulmonary Hypertension, regulatory exclusivity, Tentative Approval, Tyvaso, United States Food and Drug Administration, United Therapeutics, YUTREPIA

YUTREPIA, treprostinil, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), FDA tentative approval, regulatory exclusivity, United Therapeutics, Tyvaso

Crown Laboratories to Acquire Botox Rival Revance Therapeutics for $924M

10 months ago talkbio0Tagged Acquisition (action), Botox Rival, Crown Laboratories, Daxxify, Private Room, Revance, skincare

Crown Laboratories, Revance Therapeutics, Botox rival, Daxxify, acquisition, private deal, skincare company

Amgen Boosts Full-Year Sales Forecast Following Horizon-Driven Revenue Surge

10 months ago talkbio0Tagged Acquisition (action), amgen, Drug Industry, full-year sales, Horizon, Projections and Predictions, revenue growth

Amgen, full-year sales forecast, Horizon acquisition, revenue growth, pharmaceutical industry

Otsuka Pharmaceutical Acquires Jnana Therapeutics for $800M to Develop PKU Treatment

10 months ago talkbio0Tagged Acquisition (action), chemoproteomics, Dosage Forms, Jnana, JNT-517, Metabolic Diseases, Otsuka, Phenylketonurias, PKU, Rapid

Otsuka Pharmaceutical, Jnana Therapeutics, PKU, phenylketonuria, JNT-517, RAPID chemoproteomics platform, rare metabolic disorder, biotech acquisition